Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management

• Status: Recruiting
• Trial end date: 2023-03-15
• Target enrollment: 0
• Participant gender: All

Summary

Appropriately, half of the global population is infected with H. pylori, and it is now recognized that it causes at least 95% of all gastric cancers. Currently, the main challenge in the field of H. pylori infection is the rapidly increasing antibiotic resistance worldwide, which is causing a decline in the effectiveness of currently available eradication regimens.

The aim of the study is to assess the safety and efficacy of different H. pylori vonoprazan-based regimens compared to the commonly used standard triple therapy composed of Clarithromycin, Amoxicillin, and Proton pump inhibitor to eradicate H. pylori infection in treatment-naive patients through the determination of each regimen eradication rate and reported safety profile

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: Clarithromycin

Criteria

Inclusion Criteria:

• Patients with positive stool antigen test result for H. pylori

• Patients recently diagnosed with H. pylori infection and did not receive any treatment

Exclusion Criteria:

• Patients sensitive to any of the regimens' components

• Patients who had received a previous eradication therapy and still show positive test results

• Recent use of antimicrobial agents, proton pump inhibitors, and H2 receptor blockers within 1 month

• Patients with gastric malignancy or who underwent previous gastric surgery

• Pregnancy and lactation

• Patients with major concomitant diseases, including psychic disorders